[Efficacy and tolerability of sustained-release disopyramide in the treatment of cardiac arrhythmia. Results of a study with 593 patients].
In the context of an open multicentre study, 593 patients participated in the evaluation of sustained release disopyramide (*) in the treatment of cardiac arrhythmias. One hundred and seventy one (29%) had a ventricular arrhythmia, 382 (64%) a supraventricular arrhythmia and 40 (7%) an atrial and ventricular arrhythmia. Two hundred and seventy patients (46%)  had underlying cardiac disease. Disopyramide was administered at the mean daily dose of 462 +/- 95 mg. The effectiveness of treatment was assessed after 3 and 6 months by Holter in the group treated for ventricular arrhythmias, the responder rate was 52.6% at three months and 58.1% at 6 months. It was significantly (p < 0.001) greater in the group treated for supraventricular arrhythmias (71.3% at 3 months and 82.1% at 6 months). The Holter responder rate in patients aged over 65 (70.5% at 6 months) was high and general and cardiac acceptability similar to that in younger patients. Adverse events led to the interruption of treatment in 8.2% of patients. Thus the effectiveness/acceptability ratio of SR disopyramide makes it entirely appropriate for the treatment of cardiac arrhythmias, even in the elderly.
Lekieffre
J
J
Hôpital Cardiologique, Lille.
Vaur
L
L
Kacet
S
S
Lacroix
D
D
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004206:Disopyramide / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004562:Electrocardiography; D006801:Humans; D008875:Middle Aged
D003692:Delayed-Action Preparations; D004206:Disopyramide
Efficacité et tolérance du disopyramide à libération prolongée dans le traitement des arythmies cardiaques. Résultats d'une étude portant sur 593 patients.